Search the Newsreel

Affinity Asset Advisors (IBIO) discloses 5.07M-share, 9.99% stake in iBio

Affinity Asset Advisors, LLC and Michael Cho have disclosed a beneficial ownership of 5,068,882 shares, representing approximately 9.99%, of iBio, Inc.'s common stock. This includes 1,061,001 shares issuable upon the exercise of warrants, all subject to a 9.99% beneficial ownership limitation. The filing, a …

iBio Inc (IBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for iBio Inc (IBIO), including its current earnings forecast score, average price target, and analyst ratings. It highlights that the company's expected revenue for the next quarter is 57.14K, and the price target is USD 5.00. Most analysts …

iBio, Inc. (NASDAQ:IBIO) Given Average Rating of "Buy" by Analysts

Eight research firms have given iBio, Inc. (NASDAQ:IBIO) a consensus "Buy" rating, with four recommending "Buy" and three "Strong Buy," despite one "Sell" recommendation. The average 12-month price target for IBIO is $5.00, significantly higher than its current trading price of $1.41. The company …

iBio Inc (IBIO) Stock News Today

This page provides real-time stock news for iBio Inc (IBIO), including its latest stock price, market capitalization, and performance. It indicates that more news, earnings reports, analyst ratings, and key developments will be updated soon. The current trading data shows IBIO at $1.410, with …

iBio (IBIO) awards 430,000 stock options to its Chief Medical Officer

iBio, Inc. (IBIO) has granted its Chief Medical Officer, Molly Carr, 430,000 stock options with an exercise price of $1.40 per share, expiring in 2036. This inducement award, granted outside the company's 2023 Omnibus Incentive Plan, vests 25% after one year, with further quarterly …

iBio appoints Molly Carr as chief medical officer

iBio, Inc. (NASDAQ:IBIO) has appointed Molly Carr, M.D., as its new Chief Medical Officer. Dr. Carr will be responsible for the company's global clinical strategy, medical affairs, and regulatory initiatives, leveraging her 30 years of experience in endocrinology and metabolic disease. She was also …

iBio Inc (IBIO) Institutional Confidence

iBio Inc's institutional confidence score is 5.00, placing it 132nd in the Biotechnology & Medical Research industry. Institutional shareholding decreased by 7.72% quarter-over-quarter, with the largest individual shareholder being Bill Nygren | OAKMX, although their holdings significantly decreased. Several other institutions hold substantial shares, …

Unibios Holdings S.A. Revenue Breakdown – ATHEX:BIOSK

IBIO|iBio Inc|Price:1.385|Chg%:-0.065

iBio Inc (IBIO) is a preclinical stage biotechnology company using AI for precision antibody development, with a focus on immuno-oncology. Despite recent market underperformance, the company shows strong fundamentals, high growth potential, and a "Buy" rating from analysts with significant upside. IBIO's stock is …

iBio Inc (IBIO) Balance Sheet

This article provides a detailed balance sheet for iBio Inc (IBIO), presenting quarterly and annual financial data. It allows users to analyze the company's financial health, including assets, liabilities, and shareholders' equity over several financial years. The page also includes FAQs explaining key balance …

iBio Inc (IBIO) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides a detailed look into the shareholder structure of iBio Inc (IBIO), highlighting its major shareholders and institutional holdings. It lists the top five shareholders by proportion, including Affinity Asset Advisors LLC and EcoR1 Capital, LLC, and categorizes shareholders by type such …

iBio, Inc. Revenue Breakdown – TRADEGATE:0JV0

iBio, Inc.'s revenue breakdown shows that in the last year, the company generated 339.56K EUR, primarily from its Precision Antibodies segment which also saw 210.06K EUR the previous year. All of this revenue was attributed to the United States market.

TradingKey

This page from TradingKey provides a detailed income statement for iBio Inc (IBIO), showing quarterly and annual financial data from FY2012Q1 through FY2026Q3. It includes metrics such as total revenue, operating expenses, research and development expenses, net income, and earnings per share. The page …

iBio Inc (IBIO) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of iBio Inc (IBIO), showing its current valuation score, market capitalization, and stock price. It highlights the company's P/E ratio and notes that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed. The valuation …

Chardan Capital Maintains IBio Inc(IBIO.US) With Buy Rating, Maintains Target Price $5

Chardan Capital has reiterated its Buy rating for IBio Inc (IBIO.US), maintaining a target price of $5. This indicates the firm's continued confidence in the company's stock performance.

iBio Updates Governance Deadlines for 2026 Annual Meeting

iBio Inc. has set the date for its 2026 Annual Meeting of Stockholders for October 14, 2026, with a record date of September 1, 2026. The company has adjusted key governance deadlines due to the meeting occurring earlier than the anniversary of the 2025 …

iBio (NYSE: IBIO) schedules 2026 meeting, updates proposal deadlines

iBio, Inc. has announced the schedule for its 2026 Annual Meeting of Stockholders on October 14, 2026, with September 1, 2026, as the record date for voting eligibility. Due to the meeting being held more than 30 days earlier than the 2025 annual meeting, …

We Think iBio (NASDAQ:IBIO) Can Afford To Drive Business Growth

REG - OptiBiotix Health - Result of AGM

OptiBiotix Health plc (AIM: OPTI) Notice of Annual General Meeting

IBIO Stock Is Soaring Today After iBio's Muscle-Preserving Drug Receives Approval For Human Trial In Australia

iBio, Inc. Common Stock (IBIO) Stock Price Today: $1.47

iBio (IBIO) Stock Price, News & Analysis